Rick Winningham: Building Leaders Behind the Pipeline

Key Takeaways

• Winningham earned HBA Honorable Mentor of the Year 2025.
• Theravance’s Yupelri treats about 5,800 COPD patients weekly in U.S. hospitals.
• Mentorship builds leadership depth, accelerating drug development pipelines.
• He left Bristol Myers for a startup, now leading Theravance 25 years.
• Leadership relies on candor, high expectations, trust, and people‑first culture.

Pulse Analysis

Mentorship has become a strategic asset in the pharmaceutical sector, and Rick Winningham’s career exemplifies its power. After fifteen years at Bristol Myers Squibb, where he honed expertise in oncology and virology, he pivoted to a nascent venture that evolved into Theravance Biopharma. This bold move illustrates a broader industry trend: seasoned leaders leaving large firms to nurture innovation in smaller, agile companies. Winningham’s ability to translate mentorship into tangible outcomes—cultivating talent that can navigate complex regulatory pathways—has helped Theravance sustain a robust pipeline while maintaining scientific rigor.

Theravance’s flagship respiratory product, Yupelri (revefenacin), highlights the commercial payoff of that leadership model. The once‑daily nebulized bronchodilator now reaches approximately 5,800 COPD patients each week in U.S. hospitals, offering a simpler inhalation option that reduces readmissions. By partnering with Innoviva and leveraging the drug’s differentiated delivery, Theravance has positioned Yupelri as a growth engine, delivering both patient benefit and shareholder value. The company’s focus on expanding market penetration aligns with a broader industry push to address chronic respiratory disease, a leading cause of hospitalization and mortality in the United States.

Looking ahead, Winningham’s people‑first philosophy—centered on candor, high expectations, and trust—offers a blueprint for the next generation of biotech leaders. In an increasingly competitive landscape, fostering a culture where mentorship is embedded at every level can create a ripple effect, amplifying innovation across the ecosystem. His advice to seize imperfect opportunities and build advisory circles resonates as a practical guide for executives aiming to balance risk with impact, ensuring that the pipeline of life‑changing medicines continues to grow.